{"doi":"10.1016/j.vhri.2023.12.009","title":"Examining the Impact of the Current Reimbursement Regulation on Patient Access to Innovative Medical Devices in Taiwan: Insights From 8 Years’ Reimbursement Data","abstract":null,"journal":"Value in Health Regional Issues","year":2024,"id":606795,"datarank":0.10397207708399181,"base_score":0.6931471805599453,"endowment":0.6931471805599453,"self_citation_contribution":0.10397207708399181,"citation_network_contribution":0.0,"self_endowment_contribution":0.10397207708399181,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":1,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1557874,"name":"Sang-Soo Lee","orcid":null,"position":1,"is_corresponding":false},{"id":1557875,"name":"Chun-Ru Lin","orcid":null,"position":2,"is_corresponding":false},{"id":1557876,"name":"Haine Lee","orcid":"0000-0002-9643-1176","position":3,"is_corresponding":false},{"id":955404,"name":"Yong-Chen Chen","orcid":null,"position":4,"is_corresponding":false},{"id":1557873,"name":"Jhao-Yang Peng","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Examining the Impact of the Current Reimbursement Regulation on Patient Access to Innovative Medical Devices in Taiwan: Insights From 8 Years’ Reimbursement Data","abstract":"<h4>Objectives</h4>This study aimed to assess the impact of the reimbursement regulation of medical devices (Regulation), introduced by the National Health Insurance Administration (NHIA) in 2013, on patients' access to innovative medical devices in Taiwan.<h4>Methods</h4>Analysis of the amount of time needed from application for NHIA reimbursement for new medical devices to receiving the decision from NHIA was done using the nonreimbursement product list featured on the NHIA website. Additionally, Welch analysis of variance was used to compare the amount of time it took from application to NHIA with reimbursement decisions made by the NHIA for different nonreimbursement code categories. Further, related Pharmaceutical Benefit Reimbursement Scheme meeting minutes were analyzed to obtain more detailed information concerning medical devices' reimbursement or not.<h4>Results</h4>From December 2012 to June 2021, the overall reimbursement percentage was 56.7%, and the average amount of time between application and reimbursement was 856.7 ± 474.7 days. The mandatory reimbursement rate was about 45%. NHIA reimbursement decisions as special medical devices also take a longer amount of time, because the applicants need to agree to the decision (P < .05). The NHIA decision-making process for nonreimbursement medical devices requires a significantly longer amount of time than for general materials (eg, suture, etc) decisions.<h4>Conclusions</h4>Although the Regulation resolves payment issues, it also increases the amount of time to reach reimbursement decisions, thus hindering patient access to innovative medical devices. The study suggests that the review process needs to be simplified concerning reimbursement notification, using local real-world data to support reimbursement decisions.","is_dataset_classified":null,"base_score":0.6931471805599453,"endowment":0.6931471805599453,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"38350187","pmcid":null,"openalex_id":"https://openalex.org/W4391740589","authors":[],"funders":[],"total_grants":0,"fwci":0.6873,"citation_percentile":0.79699421,"influential_citations":0,"citation_trend":[{"year":2025,"count":1}],"oa_status":"bronze","license":"http://www.elsevier.com/open-access/userlicense/1.0/","oa_locations":[{"url":"http://www.valuehealthregionalissues.com/article/S2212109924000050/pdf","host_type":"journal"},{"url":"http://www.valuehealthregionalissues.com/article/S2212109924000050/pdf","host_type":"publisher"},{"url":"https://api.elsevier.com/content/article/PII:S2212109924000050?httpAccept=text/xml","host_type":"publisher"},{"url":"https://api.elsevier.com/content/article/PII:S2212109924000050?httpAccept=text/plain","host_type":"publisher"},{"url":"https://doi.org/10.1016/j.vhri.2023.12.009","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/38350187","host_type":"repository"}],"fields_of_study":["Health Systems, Economic Evaluations, Quality of Life","Pharmaceutical Economics and Policy","Pharmaceutical industry and healthcare"],"mesh_terms":["Equipment and Supplies","Health Services Accessibility","Humans","Insurance, Health, Reimbursement","National Health Programs","Reimbursement Mechanisms","Taiwan"],"keywords":["Reimbursement","Payment","Actuarial science","Medical record","Medicine","Business","Family medicine","Health care","Finance","Surgery","Economics","Medical devices","National Health Insurance","Reimbursement Regulation"],"sdg_mappings":[],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-07-30T05:11:18.574672Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}